Company: CMND
Filing Date: 2025-11-13
Form Type: 424B5
Source: 0001213900-25-109567
Chunk: 20

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-13
Form: 424B5
Chunk 20
---
in our operations. Although the Israeli government has in the past covered the reinstatement value of direct damages that were caused
by terrorist attacks or acts of war, we cannot assure you that this government coverage will be maintained or, if maintained, will be
sufficient to compensate us fully for damages incurred, and the government may cease providing such coverage or the coverage might not
suffice to cover potential damages. Any losses or damages incurred by us could have a material adverse effect on our business.

<div align='center'>S-8</div>

Finally, political conditions
within Israel may affect our operations. Israel has held five general elections between 2019 and 2022, and prior to October 2023, the
Israeli government pursued extensive changes to Israel’s judicial system, which sparked extensive political debate and unrest. Actual
or perceived political instability in Israel or any negative changes in the political environment, may individually or in the aggregate
adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and growth prospects.

Our failure to regain and maintain compliance with Nasdaq’s continued listing requirements could result in the delisting of the Common Shares.

The Common Shares are currently
listed for trading on Nasdaq. We must satisfy Nasdaq’s continued listing requirements, including, among other things, a minimum
bid price requirement of $1.00 per Common Share and a minimum shareholders’ equity of $2.5 million, or risk delisting, which would
have a material adverse effect on our business.

On November 3, 2025, we received
the Notification Letter from the Listing Qualifications Department of Nasdaq, notifying us that we are no longer in compliance with Nasdaq
Listing Rule 5550(b)(1). The Minimum Stockholders’ Equity Rule requires companies listed on The Nasdaq Capital Market to maintain
a minimum of $2,500,000 in stockholders' equity for continued listing. However, based on our Form 6-K filed on September 11, 2025, where
the Company filed its unaudited condensed interim consolidated financial equity for the three and nine months ended July 31, 2025,
filed on September 11, 2025, we reported a stockholders’ deficit of $1,065,668 and do not meet the alternatives of market value
of listed securities or net income from continuing operations, and we are thus non-compliant with the Minimum Stockholders’ Equity
Rule. In accordance with the